PRAC Recommends New Restrictions on Topiramate in Pregnancy

The EMA safety committee recommends new measures to limit topiramate use in young women based on recent data suggesting more neurodevelopmental disorders for offspring when it's used during pregnancy.

Related Keywords

,Pharmacovigilance Risk Assessment Committee ,Group For Mutual Recognition ,European Medicines Agency ,Co Ordination Group ,Mutual Recognition ,Decentralised Procedures ,Pregnancy ,Epilepsy ,Seizure Disorder ,Teratogen ,Neurodevelopmental Disorder ,Children ,Child ,Childhood ,Ediatrics ,Kids ,Mental Retardation ,Disability ,Europe ,European ,Fetal Growth Restriction ,Ntrauterine Growth Retardation ,Uterine ,Bomb ,Adhd ,Attention Deficit Hyperactivity Disorder ,Ttention Deficit Hyperactivity Disorder Adhd ,Autism Spectrum Disorder ,Autism ,Contraception ,Birth Control ,O ,